Dexmedetomidine Versus Ketamine as Adjuvants in Bariatric Surgery

Launched by TANTA UNIVERSITY · Dec 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective two different medications, dexmedetomidine and low-dose ketamine, are at helping manage pain after bariatric surgery, which is a weight loss surgery for people with obesity. The goal is to see if these medications can reduce the need for opioids, which are stronger painkillers that can have side effects. The study will involve 90 patients at Menoufia University Hospital, who will be divided into three groups: one group will receive dexmedetomidine, another will receive ketamine, and the third will get a placebo (a sugar pill with no active medication).

To be eligible for the study, participants should be between 18 and 60 years old, have a body mass index (BMI) over 35, and be scheduled for bariatric surgery. However, individuals with certain health issues, such as severe liver or kidney problems or a history of substance abuse, will not be able to participate. During the trial, participants can expect to be monitored for pain levels and overall satisfaction with their pain management after surgery. This research aims to find safer and more effective ways to control pain in bariatric surgery patients, which could lead to better recovery experiences.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18-60 years.
• • Both sexes.
• • Body mass index (BMI) \> 35 kg/m², scheduled for bariatric surgery.
• • American Society of Anesthesiologists (ASA) physical status I-II.
• Exclusion Criteria:
• • History of hypersensitivity to dexmedetomidine or ketamine.
• • History of substance abuse or chronic opioid use.
• • American Society of Anesthesiologists (ASA) physical status III or IV.
• • Severe hepatic or renal impairment.
• • Cardiopulmonary disorders.
• • Severe diabetes mellitus.
• • Psychiatric disorders, seizures, uncontrolled hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg), or heart block.